Drug Information
Drug (ID: DG01790) and It's Reported Resistant Information
Name |
Picric acid
|
||||
---|---|---|---|---|---|
Synonyms |
PICRIC ACID; 2,4,6-Trinitrophenol; Trinitrophenol; 88-89-1; Acide picrique; Carbazotic acid; Picronitric acid; Melinite; Phenol trinitrate; Picral; Nitroxanthic acid; Pikrinsaeure; Phenol, 2,4,6-trinitro-; Pikrinezuur; Acido picrico; Pikrynowy kwas; 2-Hydroxy-1,3,5-trinitrobenzene; Kyselina pikrova; 1,3,5-Trinitrophenol; C.I. 10305; 2,4,6-Trinitrofenol; 2,4,6-Trinitrofenolo; 2,4,6-Trinitrophenyl; UNII-A49OS0F91S; NSC 36947; CI 10305; A49OS0F91S; CHEBI:46149; Picric acid, dry; Picric acid, wet; 2,6-Trinitrofenol; Pertite; Picric acid (dry); Picric acid (wet); 1,5-Trinitrophenol; 2,6-Trinitrofenolo; 2,6-Trinitrophenol; Phenol,4,6-trinitro-; Phenoltrinitrate; Acidum picrinicum; WLN: WNR BQ CNW ENW; 2-Hydroxy-1,5-trinitrobenzene; Pikrinezuur [Dutch]; Pikrinsaeure [German]; Picricum acidum; Acide picrique [French]; Acido picrico [Italian]; Pikrynowy kwas [Polish]; Kyselina pikrova [Czech]; 2,4,6-Trinitrophenol (Picric Acid); CCRIS 3106; Trinitrophenol [NF]; 2,4,6-Trinitrofenol [Dutch]; HSDB 2040; 2,4,6-Trinitrofenolo [Italian]; EINECS 201-865-9; NA1344; UN0154; UN1344; Reflorit; AI3-15403; Hager's reagent; Picric acid solution; Picric acid, p.a.; Lyddite (Salt/Mix); Ecrasite (Salt/Mix); Schimose (Salt/Mix); SCHEMBL8745; NA 1344 (Salt/Mix); UN 1344 (Salt/Mix); CHEMBL108541; DTXSID4025909; Picric acid, dry or wetted with < 30% water, by mass; SCHEMBL14419782; BDBM34612; cid_3241713; Trinitrophenol, dry or wetted with < 30% water, by mass; NSC36947; NSC56147; ZINC1883067; 3-Hydroxy-2,4,6-trinitrobenzenide; NSC-36947; NSC-56147; STL199171; ZINC71129432; AKOS008966816; DB03651; MCULE-8917344355; UN 0154; Picric acid, wet, with not <10% water; DB-057108; Picric acid, moistened with water, >=98%; FT-0609916; Picric acid, SAJ special grade, >=99.5%; 2-methylbenzo[g][1,3]benzoxazole;picric acid; Picric acid solution, 0.9-1.1% (alkalimetric); Picric acid solution, 1.3% in H2O (saturated); A842990; Q189298; SR-01000944524; 1-methyl-3,4-dihydro-2H-beta-carboline;picric acid; 2,4,6-Trinitrophenol 10 microg/mL in Acetonitrile; SR-01000944524-1; 2,4,6-Trinitrophenol 100 microg/mL in Acetonitrile; Trinitrophenol, wetted with not <30% water, by mass; 2-methylbenzo[g][1,3]benzoxazole;2,4,6-trinitrophenol; Picric acid solution, ~1.3% in H2O, solution (saturated aqueous); Picric acid, wet, with not <10% water [NA1344] [Flammable solid]; Trinitrophenol or picric acid, dry or wetted with <30% water, by mass; Picric acid solution, 100 mug/mL in acetonitrile, PESTANAL(R), analytical standard; Picric acid, purum, moistened with >=40% water, >=98.0% (calc. on dry substance, T); Trinitrophenol, wetted with not <30% water, by mass [UN1344] [Flammable solid]; Trinitrophenol or picric acid, dry or wetted with <30% water, by mass [UN0154] [Explosive 1.1D]
Click to Show/Hide
|
||||
Structure | |||||
Drug Resistance Disease(s) |
Disease(s) with Clinically Reported Resistance for This Drug
(1 diseases)
Inflammation [ICD-11: 1A00-CA43]
[1]
Disease(s) with Resistance Information Validated by in-vivo Model for This Drug
(1 diseases)
Trigeminal neuralgia [ICD-11: 8B82]
[2]
Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug
(1 diseases)
Irritable bowel syndrome [ICD-11: DD91]
[3]
|
||||
Target | . | NOUNIPROTAC | [2] | ||
Click to Show/Hide the Molecular Information and External Link(s) of This Drug | |||||
IsoSMILES |
C1=C(C=C(C(=C1[N+](=O)[O-])O)[N+](=O)[O-])[N+](=O)[O-]
|
||||
InChI |
InChI=1S/C6H3N3O7/c10-6-4(8(13)14)1-3(7(11)12)2-5(6)9(15)16/h1-2,10H
|
||||
InChIKey |
OXNIZHLAWKMVMX-UHFFFAOYSA-N
|
||||
PubChem CID |
Type(s) of Resistant Mechanism of This Drug
EADR: Epigenetic Alteration of DNA, RNA or Protein
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-01: Infectious/parasitic diseases
Inflammation [ICD-11: 1A00-CA43]
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Key Molecule: Long non-protein coding RNA (MIRT2) | [1] | |||
Molecule Alteration | Down-regulation | Interaction |
||
Resistant Disease | TNF-alpha-triggered inflammation [ICD-11: 3B81.Z] | |||
Experimental Note | Identified from the Human Clinical Data | |||
Experiment for Molecule Alteration |
qRT-PCR; Western bloting analysis; Overexpression assay; Knockdown assay; ELISA assay; Mimic assay | |||
Mechanism Description | Long non-coding RNA Mirt2 prevents TNF-alpha-triggered inflammation via the repression of microRNA-101. |
ICD-08: Nervous system diseases
Trigeminal neuralgia [ICD-11: 8B82]
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Key Molecule: Predicted gene 14461 (Gm14461) | [2] | |||
Molecule Alteration | Up-regulation | Expression |
||
Resistant Disease | Trigeminal neuralgia [ICD-11: 8B82.0] | |||
Experimental Note | Discovered Using In-vivo Testing Model | |||
In Vivo Model | C57BL/6 J mouse model | Mus musculus | ||
Experiment for Molecule Alteration |
qRT-PCR; Western bloting analysis; Knockdown assay; Overexpression assay; Mimic | |||
Mechanism Description | Gm14461 promoted pain transmission (reduced MWT value) in a CCI-ION-induced mouse TN model. |
ICD-13: Digestive system diseases
Irritable bowel syndrome [ICD-11: DD91]
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Key Molecule: Taurine up-regulated 1 (TUG1) | [3] | |||
Molecule Alteration | Down-regulation | Interaction |
||
Resistant Disease | Irritable bowel syndrome [ICD-11: DD91.0] | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | ICCs | Breast | Homo sapiens (Human) | CVCL_B5N7 |
Experiment for Molecule Alteration |
qRT-PCR; Western bloting analysis; Overexpression assay | |||
Experiment for Drug Resistance |
CCK8 assay; Flow cytometry assay | |||
Mechanism Description | TUG1 attenuated TNF-alpha-caused apoptosis and inflammatory response in ICC by down-regulating miR-127 and then inactivating NF-kappa-B and Notch pathways. |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.